X hits on this document

103 views

0 shares

0 downloads

0 comments

17 / 34

PBC and PSC

PBC: Treatment

ursodeoxycholic acid (UDCA)

-

improves biochemistry, histology, and survival

-

13-15 mg/kg/day divided TID

-

FDA approved for PBC

budesonide and UDCA

-

well studied only in UDCA non-responders; no benefit in prognosis models

-

in naïve patients, improved biochemistry and histology (vs. UDCA alone), but no information on prognosis

AMA-negative PBC seems to behave and respond the same as PBC, but may overlap with autoimmune hepatitis.

Document info
Document views103
Page views103
Page last viewedFri Jan 20 20:38:16 UTC 2017
Pages34
Paragraphs559
Words1582

Comments